12/23
04:09 pm
aray
Accuray (NASDAQ:ARAY) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Accuray (NASDAQ:ARAY) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/20
11:01 am
aray
Global Veterinary Stereotactic Radiosurgery System Market to Hit USD 7.46 Billion by 2032 – SNS Insider [Yahoo! Finance]
Low
Report
Global Veterinary Stereotactic Radiosurgery System Market to Hit USD 7.46 Billion by 2032 – SNS Insider [Yahoo! Finance]
12/15
05:24 pm
aray
Accuray announces first phase of comprehensive strategic, operational, and organizational transformation plan; company expects first phase to improve annualized operating profitability by approximately $25 million and set the stage for renewed growth [Yah
Low
Report
Accuray announces first phase of comprehensive strategic, operational, and organizational transformation plan; company expects first phase to improve annualized operating profitability by approximately $25 million and set the stage for renewed growth [Yah
12/15
05:00 pm
aray
Accuray announces first phase of comprehensive strategic, operational, and organizational transformation plan; company expects first phase to improve annualized operating profitability by approximately $25 million and set the stage for renewed growth
Low
Report
Accuray announces first phase of comprehensive strategic, operational, and organizational transformation plan; company expects first phase to improve annualized operating profitability by approximately $25 million and set the stage for renewed growth
12/13
08:50 am
aray
Accuray Incorporated (NASDAQ:ARAY) is largely controlled by institutional shareholders who own 59% of the company [Yahoo! Finance]
Medium
Report
Accuray Incorporated (NASDAQ:ARAY) is largely controlled by institutional shareholders who own 59% of the company [Yahoo! Finance]
11/26
02:00 pm
aray
Accuray (NASDAQ:ARAY) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Accuray (NASDAQ:ARAY) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/6
08:10 am
aray
Accuray (NASDAQ:ARAY) had its price target lowered by analysts at BTIG Research from $5.00 to $4.00. They now have a "buy" rating on the stock.
Medium
Report
Accuray (NASDAQ:ARAY) had its price target lowered by analysts at BTIG Research from $5.00 to $4.00. They now have a "buy" rating on the stock.
11/5
04:05 pm
aray
Accuray Reports Fiscal 2026 First Quarter Financial Results
High
Report
Accuray Reports Fiscal 2026 First Quarter Financial Results
10/31
04:52 pm
aray
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules [Yahoo! Finance]
Low
Report
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules [Yahoo! Finance]
10/31
04:03 pm
aray
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
Low
Report
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
10/28
07:35 am
aray
Accuray to Report First Quarter Fiscal 2026 Financial Results on November 5, 2025
Medium
Report
Accuray to Report First Quarter Fiscal 2026 Financial Results on November 5, 2025
10/20
09:20 am
aray
Accuray Accelerates Transformation Efforts with Appointment of Experienced Executive Leaders to Drive Performance and Growth
Low
Report
Accuray Accelerates Transformation Efforts with Appointment of Experienced Executive Leaders to Drive Performance and Growth
10/19
09:01 am
aray
Accuray (NASDAQ:ARAY) Is Finding It Tricky To Allocate Its Capital [Yahoo! Finance]
Low
Report
Accuray (NASDAQ:ARAY) Is Finding It Tricky To Allocate Its Capital [Yahoo! Finance]
10/8
07:55 am
aray
Accuray Announces Milestone for Cancer Patients in Melbourne, Australia with First SBRT Treatments Using the CyberKnife® System [Yahoo! Finance]
Medium
Report
Accuray Announces Milestone for Cancer Patients in Melbourne, Australia with First SBRT Treatments Using the CyberKnife® System [Yahoo! Finance]
10/8
07:35 am
aray
Accuray Announces Milestone for Cancer Patients in Melbourne, Australia with First SBRT Treatments Using the CyberKnife® System
Low
Report
Accuray Announces Milestone for Cancer Patients in Melbourne, Australia with First SBRT Treatments Using the CyberKnife® System
10/3
02:37 pm
aray
Accuray (NASDAQ:ARAY) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Accuray (NASDAQ:ARAY) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
9/30
08:22 am
aray
Accuray and the University of Wisconsin-Madison Announce Memorandum of Understanding to Advance Online Adaptive Radiotherapy in Support of Improving Cancer Patient Care [Yahoo! Finance]
Low
Report
Accuray and the University of Wisconsin-Madison Announce Memorandum of Understanding to Advance Online Adaptive Radiotherapy in Support of Improving Cancer Patient Care [Yahoo! Finance]
9/30
07:35 am
aray
Accuray and the University of Wisconsin-Madison Announce Memorandum of Understanding to Advance Online Adaptive Radiotherapy in Support of Improving Cancer Patient Care
Low
Report
Accuray and the University of Wisconsin-Madison Announce Memorandum of Understanding to Advance Online Adaptive Radiotherapy in Support of Improving Cancer Patient Care
9/30
12:00 am
aray
Accuray Incorporated (ARAY) Shareholder/Analyst Call Transcript [Seeking Alpha]
Medium
Report
Accuray Incorporated (ARAY) Shareholder/Analyst Call Transcript [Seeking Alpha]
9/29
05:03 am
aray
Accuray introduces new radiotherapy solution for adaptive care [Yahoo! Finance]
Low
Report
Accuray introduces new radiotherapy solution for adaptive care [Yahoo! Finance]
9/26
07:46 am
aray
Accuray Launches All-in-One Radiotherapy Solution With Advanced Capabilities Designed to Set a New Standard in Cancer Care [Yahoo! Finance]
Medium
Report
Accuray Launches All-in-One Radiotherapy Solution With Advanced Capabilities Designed to Set a New Standard in Cancer Care [Yahoo! Finance]
9/26
07:35 am
aray
Accuray Launches All-in-One Radiotherapy Solution With Advanced Capabilities Designed to Set a New Standard in Cancer Care
Low
Report
Accuray Launches All-in-One Radiotherapy Solution With Advanced Capabilities Designed to Set a New Standard in Cancer Care